Brewing blood

Abstract

In this issue of Blood, Giarratana et al. provide an important proof of principle in the quest for biotechnology's equivalent of the Holy Grail of blood transfusion: ex vivo manufacture of human red cells (RBCs) for therapeutic use (see figure).